This randomized phase III trial was conducted to confirm noninferiority of amrubicin plus cisplatin ( AP ) compared with irinotecan plus cisplatin ( IP ) in terms of overall survival ( OS ) in chemotherapy-naive patients with extensive-disease ( ED ) small-cell lung cancer ( SCLC ) .